We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Rapid Immunoassay Shows Potential for Lyme Disease Diagnosis

By LabMedica International staff writers
Posted on 28 Oct 2019
A three-antigen-based immunoassay for diagnosis of Lyme disease has the potential to be developed for point-of-care use.

Lyme disease, which is caused by the spiral-shaped bacterium Borrelia burgdorferi, may be difficult to diagnose, as it causes a wide range of symptoms, from fever and rash to neurologic and cardiac symptoms and joint pain.

The most widely used method for Lyme diagnosis is testing for antibodies in the blood by ELISA and Western blot. More...
A two-tiered protocol is recommended by the [U.S.] Centers for Disease Control and Prevention (CDC): the sensitive ELISA test is performed first, and if it is positive or equivocal, then the more specific Western blot is run. However, the reliability of the CDC two-tiered protocol is controversial.

Studies have shown that the Western blot IgM has a specificity of 94–96% for individuals with clinical symptoms of early Lyme disease. The initial ELISA test has a sensitivity of about 70%, and in two-tiered testing, the overall sensitivity is only 64%, although this rises to 100% in the subset of people with disseminated symptoms, such as arthritis. Erroneous test results have been widely reported in both early and late stages of the disease, and can be caused by several factors, including antibody cross-reactions from other infections, including Epstein–Barr virus and cytomegalovirus, as well as herpes simplex virus.

As an alternative to the two-tiered protocol, investigators at NIH/National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA) and collaborators at several institutions including Columbia University (New York, NY, USA) and the University of Tennessee Health Science Center (Memphis, USA) developed a sensitive immunoassay based on three Borrelia burgdorferi antigens.

The investigators used human serum rigorously characterized as acute and convalescent early Lyme disease, Lyme arthritis, and post treatment Lyme disease syndrome, as well as the necessary control samples to select the best of 12 Borrelia burgdorferi proteins to improve their microfluidic assay (mChip-Ld). The operation of mChip is similar to that of ELISA for determining serum antibody concentrations. The mChip contains 10 zones, which detect the passage of a small amount (about one microliter) of blood. The results can be obtained in a color-coded format in about 15 minutes.

The investigators selected three antigens (3Ag) to include in the mChip-Ld: VlsE and a proprietary synthetic 33-mer (repeat units) peptide (PepVF) to capture sensitivity in all disease stages, and OspC for early Lyme disease.

Results revealed that these biomarkers were more effective than those previously used at identifying signs of Lyme disease infection in early stage samples, possibly as these antigens were able to detect antibodies that peaked in the first two to six weeks following infection.

The investigators suggested that their results opened the door for the development of a single, rapid, multiplexed diagnostic test for point-of-care use that could be designed to identify Lyme disease stage.

The study was published in the October 9, 2019, online edition of the Journal of Clinical Microbiology.

Related Links:
NIH/National Institute of Allergy and Infectious Diseases
Columbia University
University of Tennessee Health Science Center


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.